Why did PHASQ stock fall 99.00% today?

PHASQ stock declined primarily from extremely low liquidity, ongoing Chapter 11 restructuring history, and market notices about potential delisting. Those factors combined with thin volume drove a severe price move during market hours.

What is Meyka AI’s grade for PHASQ stock and what it means?

Meyka AI rates PHASQ **62.91/100 | Grade B | Suggestion: HOLD**. The grade reflects benchmark and sector comparisons, financial growth, metrics, and analyst signals. It is informational and not investment advice.

Is there a price forecast for PHASQ stock?

Meyka AI's forecast model projects a 12‑month target of **USD 0.00**, implying near complete downside versus the current quote. Forecasts are model‑based projections and not guarantees.

Can PHASQ stock recover if clinical news is positive?

Positive clinical or restructuring news could lift PHASQ stock from current levels, but recovery would depend on financing, listing status, and investor confidence. Any rally would face steep liquidity and dilution challenges.

US Stocks

PHASQ PhaseBio Pharmaceuticals (PNK) down 99.00% 06 Feb 2026: top loser insights

ByDanny Kontos February 7, 2026

PHASQ stock collapsed during market hours on 06 Feb 2026, trading at USD 0.000001 and down 99.00% on the day on the PNK exchange in the United States. Volume was light at 2,500 shares versus an average of 22,310, while the one‑year high sits at USD 0.03990. This move places PhaseBio Pharmaceuticals, Inc. (PHASQ) among the session’s top losers as investors react to end‑stage restructuring and delisting risk. We examine the drivers, financials, and what scenarios could matter next for traders tracking PHASQ stock.